Aggregator

Beloved grocery chain Trader Joe's is facing a new lawsuit from a group of customers who are alleging there is not enough caffeine in their coffee.

Carson Beck has a new home.

The boss of the controversial tech company with UK government contracts published a 22-point plan on the future of the West.

The Americans, who haven’t won on foreign soil since 1993, need experience more than anything.

A California winery co-owned by Democrat Rep. Ilhan Omar's husband has shut its doors for good amid scrutiny of the congresswoman’s family’s wealth.

PITTSBURGH – One day after drafting Matthew Stafford’s eventual heir apparent, they got their veteran quarterback another tight end The club selected Ohio State’s Max Klare with the 61st overall selection in the second round of the NFL draft. That means the Rams now have six tight ends under contract for the 2026 season, including...

The first move of the Islanders' offseason came Friday night.

Billionaire Tom Steyer was blasted for his comments on whether he should pay more taxes.

David Stearns took some big swings this offseason in making over the Mets roster, and a 12-game losing streak just two weeks into the year might lead an executive to some regrets.

The private investigator is working with Eric Swalwell's lawyer, per a report.

The Mets have gotten some clarity on Francisco Lindor’s left calf strain, and it’s not good news.

Following backlash for his criticism of Dodgers fans, a Cubs star told The Post on Friday "I don’t f—king regret s—t."

A lack of offense was at the root of the Rangers’ issues this season, but defensively, first-year head coach Mike Sullivan implemented a puck pursuit-heavy system designed to support one another as a five-man unit.

Trump Administration Seeks Pause Of Lawsuit Challenging Vaccine Recommendations

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Trump administration lawyers on April 23 said they are still considering whether to appeal a ruling that blocked the rollback of guidance on some vaccines.

Health Secretary Robert Kennedy Jr. on Capitol Hill in Washington on April 22, 2026. Madalina Kilroy/The Epoch Times

The lawyers said in a filing that pausing the litigation over the guidance pending the resolution of any appeal that is filed would “promote judicial economy and avoid burdens on government agencies that may be rendered unnecessary by a decision on any appeal.”

For instance, if an appeal is filed, the U.S. Court of Appeals for the First Circuit may dismiss some or all of the claims by plaintiffs in the case, which would eliminate the need for the government to produce records sought by plaintiffs, the lawyers told U.S. District Judge Brian Murphy in a motion to stay proceedings pending resolution of any appeal.

“At a minimum, a First Circuit decision on any appeal could narrow the issues in dispute and provide guidance on how to resolve any remaining issues,” the motion stated. “If Defendants continue producing administrative records and the parties start briefing cross-motions for summary judgment before Defendants’ time to appeal has run and before the First Circuit has an opportunity to weigh in on any appeal, there is a significant potential for wasted time and resources.”

Murphy in March stayed the updates made to Centers for Disease Control and Prevention vaccine guidance under Health Secretary Robert F. Kennedy Jr., resulting in the guidance reverting to what had been in place in mid-2025.

Murphy concluded that Kennedy and other officials did not follow proper procedure in updating the guidance and appointing new members to the CDC’s vaccine advisory committee.

That stay would remain in effect even if Murphy approves the requested motion, administration lawyers said.

The lawyers did not say why no appeal has been lodged against Murphy’s decision. They asked him to stay proceedings in the case until whichever comes later: May 15 or the resolution of any appeal the defendants may file.

The deadline to appeal Murphy’s preliminary injunction is May 15.

Shortly after the injunction was issued, the Department of Health and Human Services said it would prevail in an appeal. The department has declined to answer questions about why an appeal has not yet been lodged.

“Unless officially announced by us, any assertions about what we are doing next is baseless speculation,” a department spokesperson told The Epoch Times in March.

The litigation was brought by multiple health care groups, including the American Academy of Pediatrics.

Government lawyers conferred with plaintiffs, who opposed the motion to stay the proceedings.

Tyler Durden Fri, 04/24/2026 - 21:00

Alasdair Keane visits the underground insect farm turning food waste into animal feed.

A tree trimmer stranded high above a San Jose neighborhood was dramatically airlifted to safety Friday after suffering a medical emergency while working roughly 75 feet up a palm tree.

Brooklyn Councilman Chi Ossé was cuffed Wednesday as he tried to prevent an eviction he claimed stemmed from “deed theft.”

At the 2026 NFL Draft, Mark Ingram III took his first steps toward stardom.

FDA Grants Quick Review Psychedelic Drugs, First Approvals Could Come As Soon As Summer

The FDA announced new steps to speed up research on psychedelic treatments for serious mental health conditions, following an executive order from President Donald Trump directing agencies to expand access to emerging therapies, CNBC and NBC reported this morning:

In a press release Friday, FDA commissioner Marty Makary said the medications “have the potential to address the nation’s mental health crisis, including conditions like treatment resistant depression, alcoholism and other serious mental health and substance abuse conditions.” On Monday, Makary told NBC News that with the accelerated application process, the FDA could potentially approve the first psychedelic drug by the end of summer.

The agency said this effort could support new treatments for conditions like treatment-resistant depression, PTSD, and substance use disorders. Measures include prioritizing drugs with early promising results and offering incentives to companies studying compounds such as psilocybin and methylone. It also approved an early clinical trial for noribogaine, marking the first time a drug of its kind will be studied in the U.S.

Officials emphasized that these actions do not mean the treatments are approved or proven safe. All research will be closely monitored to ensure it meets strict scientific and safety standards.

Popular psychedelic names like Compass Pathways and AtaiBeckley have turned positive YTD on on the news out the last few days.

"The executive order I'm signing, we're actually signing the executive order today, is really a moment," Trump said at the signing event days ago. "These treatments are currently in the advanced stages of clinical trials to ensure that they're both safe and effective for the American patients."

Trump's order, signed on Saturday, directs the FDA to prioritize review of certain breakthrough-designated psychedelic therapies, expands potential access under the Right to Try Act, commits at least $50 million in federal funding for state partnerships, and encourages closer coordination among HHS, the FDA, the VA, and private-sector researchers.

"In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans," Trump said, citing the veteran suicide rate.

The order also instructs the Justice Department to move quickly on rescheduling any psychedelic-based product that successfully completes Phase 3 trials and receives FDA approval.

Trump continued, "And the nice part is we're actually doing this early, but it has been going on. Research has been going on for quite some time. But, you know, usually with things like this, nothing ever happens, no matter how the research ends up, but we're changing that. This order will clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA and the Department of Veterans Affairs, and facilitate fast rescheduling of any psychedelic drugs that become FDA-approved." 

As we wrote days ago, these stocks are starting to go 'mainstream' after being ignored and out of the limelight for years. Zero Hedge contributor Quoth the Raven has named the sector his “best idea” sector for 2026.

Tyler Durden Fri, 04/24/2026 - 20:30

IKEA will open its first Culver City, city-center format store on May 2, expanding its Southern California footprint beyond Burbank, Carson and Covina.